Shares of Afya Limited (NASDAQ:AFYA – Get Free Report) saw strong trading volume on Tuesday. Approximately 525,763 shares traded hands during trading, an increase of 208% from the average daily volume of 170,777 shares. The stock last traded at $10.57 and had previously closed at $10.64.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on AFYA shares. Zacks Research upgraded shares of Afya from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Wall Street Zen raised Afya from a “hold” rating to a “buy” rating in a research report on Saturday, September 5th. JPMorgan Chase & Co. raised Afya from a “neutral” rating to an “overweight” rating and lowered their target price for the stock from $21.00 to $19.00 in a research report on Wednesday, October 7th. Weiss Ratings downgraded Afya from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Finally, Bradesco Corretora upgraded Afya to an “outperform” rating and set a $17.00 price target on the stock in a research report on Thursday, September 24th. Two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.25.
Get Our Latest Stock Analysis on AFYA
Afya Price Performance
The company has a fifty day moving average of $13.96 and a 200-day moving average of $14.31. The firm has a market cap of $994.74 million, a P/E ratio of 6.45, a P/E/G ratio of 1.83 and a beta of 0.34. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.20 and a quick ratio of 2.20.
Afya (NASDAQ:AFYA – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. Afya had a return on equity of 17.58% and a net margin of 20.55%. The business had revenue of $187.80 million during the quarter, compared to analyst estimates of $189.62 million. On average, sell-side analysts anticipate that Afya Limited will post 1.72 EPS for the current fiscal year.
Insider Buying and Selling
In other Afya news, insider Santos Welder Ferreira sold 4,161 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $13.30, for a total value of $55,341.30. Following the completion of the transaction, the insider owned 35,000 shares in the company, valued at $465,500. This trade represents a 10.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Institutional Investors Weigh In On Afya
An institutional investor recently bought a new stake in Afya stock. Engineers Gate Manager LP acquired a new stake in shares of Afya Limited (NASDAQ:AFYA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 21,882 shares of the company’s stock, valued at approximately $325,000. 88.02% of the stock is currently owned by institutional investors and hedge funds.
About Afya
Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.
Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.
The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.
Read More
- Five stocks we like better than Afya
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
- Off-Price, High-Yield: Why Ross Stores Is Defying the Retail Slump
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
